Dan Bonner

Company: Seaport Therapeutics

Job title: Co-Founder & Senior Vice President, Platform

Seminars:

Discovery & Selection of Novel Lymphatic-Targeted Prodrug Candidates to Treat Neuropsychiatric Disorders Using Clinical Evidence 1:30 pm

Selecting neuropsychiatric targets based on clinically validated mechanisms with existing limitations Using Seaport’s Glyph platform, a lymphatic-targeted prodrug technology to overcome these limitations, such as poor oral bioavailability or side effects of neuropsychiatric treatments and beyond. Sharing examples of the approach of identifying drugs with proven clinical efficacy and applying the Glyph platform to address…Read more

day: Day Two Track A - PM